HPCTC enters a multi-year partnership to establish a database enriched for subjects with NAFLD/NASH as a member of ProSciento’s NASH PASS Site Network HIGH POINT, N.C., June 19, 2019 /PRNewswire/ — High Point Clinical Trials Center, LLC, the largest...
Balixafortide is the most advanced and only CXCR4 antagonist in development in a pivotal Oncology global registration trial. Polyphor today announced the enrollment of the first patient in its FORTRESS clinical trial, the pivotal Phase III study evaluating...
By Rosamund Round, Victor Cheng, George Lee, Alberto Grignolo, Sy Pretorius at Pharmaceutical Executive Findings from a recent Economist Intelligence Unit (EIU) report1 indicate that the use of patient-centric clinical trials—that is, trials that are designed and...
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a leading U.S.-based multi-platform clinical-stage gene therapy company, today announces that patient dosing has commenced in the open-label, Phase 1 clinical trial of RP-A501, the Company’s adeno-associated...
Geneva, Switzerland and Boston, MA – June 19, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a...
Email
Text